Geron Highlights Product Launch from Collaboration with Corning – the Synthemax™ Surface for Scalable Growth of Human Emb...
03 Marzo 2010 - 10:30PM
Business Wire
Geron Corporation (Nasdaq:GERN) today announced that Corning
Incorporated (NYSE:GLW) has launched the Synthemax™ surface, a new
synthetic matrix for growing human embryonic stem cells (hESCs),
developed under a collaboration and license agreement between the
two companies.
Geron and Corning have been working together to develop
synthetic surface matrices to enhance the scalability of
hESC-derived product manufacturing. The Corning® Synthemax™ surface
is the first such product to be commercialized.
“The synthetic growth matrix technology developed in our
collaboration with Corning is an enabling platform to be used by
Geron in producing new cell therapies for patients with
degenerative diseases,” said Jane S. Lebkowski, Ph.D., Geron’s
senior vice president and chief scientific officer, regenerative
medicine. “This technology allows for more consistent, reliable and
cost-effective manufacturing of hESC-derived products.”
hESCs express telomerase and have the capacity for indefinite
replication in the undifferentiated state while retaining the
potential to develop into all the cell types of the human body
(pluripotency). With these properties, hESCs are the ideal starting
material for large-scale production of cell therapies. To date,
hESCs have been grown in complex culture systems that use
biological materials, such as culture vessels with biological
surface coatings.
Biological materials present a challenge for manufacturing
hESC-derived products at scales required for therapeutic
applications. Biological surface coatings are expensive to produce,
have lot-to-lot variability, and are subject to costly testing to
ensure that they are pathogen-free.
Synthetic growth surfaces enable readily scalable and
cost-effective production of undifferentiated hESCs and their
differentiated therapeutic cells. Geron and Corning scientists
presented data showing robust hESC growth and differentiation on
the Synthemax™ surface at the September 2009 World Stem Cell
Summit.
The Synthemax™ surface supports the long-term propagation of
hESCs cultured in a defined, xeno-free medium, while
maintaining:
- stable proliferation rates;
- characteristic phenotypic marker
profile of the undifferentiated state;
- normal karyotype; and
- pluripotency.
The laboratory products using the Synthemax™ surface and other
synthetic surface matrices developed under the collaboration
between Geron and Corning will be commercialized by Corning. Geron
will receive a royalty on product sales and has exclusive rights to
use the synthetic surface matrices, including the Synthemax™
surface, in the manufacturing of certain therapeutic products.
Currently, Corning’s 6-well plate with the Synthemax™ surface is
available in North America.
About Geron
Geron is developing first-in-class biopharmaceuticals for the
treatment of cancer and chronic degenerative diseases, including
spinal cord injury, heart failure and diabetes. The company is
advancing an anti-cancer drug and a cancer vaccine that target the
enzyme telomerase through multiple clinical trials in different
cancers. For more information, visit www.geron.com.
About Corning Incorporated
Corning Incorporated (www.corning.com) is the world leader in
specialty glass and ceramics. Drawing on more than 150 years of
materials science and process engineering knowledge, Corning
creates and makes keystone components that enable high-technology
systems for consumer electronics, mobile emissions control,
telecommunications and life sciences. Our products include glass
substrates for LCD televisions, computer monitors and laptops;
ceramic substrates and filters for mobile emission control systems;
optical fiber, cable, hardware & equipment for
telecommunications networks; optical biosensors for drug discovery;
and other advanced optics and specialty glass solutions for a
number of industries including semiconductor, aerospace, defense,
astronomy and metrology.
Geron Safe Harbor
This news release may contain forward-looking statements made
pursuant to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Investors are cautioned that
statements in this press release regarding potential applications
of Geron’s human embryonic stem cell technology constitute
forward-looking statements that involve risks and uncertainties,
including, without limitation, risks inherent in the development
and commercialization of potential products, uncertainty of
clinical trial results or regulatory approvals or clearances, need
for future capital, dependence upon collaborators and maintenance
of our intellectual property rights. Actual results may differ
materially from the results anticipated in these forward-looking
statements. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed
from time to time in Geron’s periodic reports, including the annual
report on Form 10-K for the year ended December 31, 2009.
Corning Forward-Looking and Cautionary Statements
This press release contains
“forward-looking statements” (within the meaning of the Private
Securities Litigation Reform Act of 1995), which are based on
current expectations and assumptions about Corning’s financial
results and business operations, that involve substantial risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include: the effect of global
political, economic and business conditions; conditions in the
financial and credit markets; currency fluctuations; tax rates;
product demand and industry capacity; competition; reliance on a
concentrated customer base; manufacturing efficiencies; cost
reductions; availability of critical components and materials; new
product commercialization; pricing fluctuations and changes in the
mix of sales between premium and non-premium products; new plant
start-up or restructuring costs; possible disruption in commercial
activities due to terrorist activity, armed conflict, political
instability or major health concerns; adequacy of insurance; equity
company activities; acquisition and divestiture activities; the
level of excess or obsolete inventory; the rate of technology
change; the ability to enforce patents; product and components
performance issues; stock price fluctuations; and adverse
litigation or regulatory developments. These and other risk factors
are detailed in Corning’s filings with the Securities and Exchange
Commission. Forward-looking statements speak only as of the day
that they are made, and Corning undertakes no obligation to update
them in light of new information or future events.
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Corning (NYSE:GLW)
Storico
Da Lug 2023 a Lug 2024